These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2881320)

  • 1. Double blind controlled trials of cholecystokinin octapeptide in neuroleptic-refractory schizophrenia.
    Peselow E; Angrist B; Sudilovsky A; Corwin J; Siekierski J; Trent F; Rotrosen J
    Psychopharmacology (Berl); 1987; 91(1):80-4. PubMed ID: 2881320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin-octapeptide in chronic schizophrenia: a double-blind placebo-controlled study.
    Nair NP; Bloom DM; Debonnel G; Schwartz G; Mosticyan S
    Prog Neuropsychopharmacol Biol Psychiatry; 1984; 8(4-6):711-4. PubMed ID: 6152344
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of ceruletide in schizophrenia.
    Hommer DW; Pickar D; Roy A; Ninan P; Boronow J; Paul SM
    Arch Gen Psychiatry; 1984 Jun; 41(6):617-9. PubMed ID: 6329121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Untangling the effects of hunger, anxiety, and nausea on energy intake during intravenous cholecystokinin octapeptide (CCK-8) infusion.
    Greenough A; Cole G; Lewis J; Lockton A; Blundell J
    Physiol Behav; 1998 Nov; 65(2):303-10. PubMed ID: 9855480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholecystokinin peptides, dopamine and schizophrenia--a review.
    Nair NP; Lal S; Bloom DM
    Prog Neuropsychopharmacol Biol Psychiatry; 1985; 9(5-6):515-24. PubMed ID: 2868491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group.
    Small JG; Hirsch SR; Arvanitis LA; Miller BG; Link CG
    Arch Gen Psychiatry; 1997 Jun; 54(6):549-57. PubMed ID: 9193196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of parenteral nutrition-associated cholestasis with cholecystokinin-octapeptide.
    Teitelbaum DH; Han-Markey T; Schumacher RE
    J Pediatr Surg; 1995 Jul; 30(7):1082-5. PubMed ID: 7472937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholecystokinin prevents parenteral nutrition induced biliary sludge in humans.
    Sitzmann JV; Pitt HA; Steinborn PA; Pasha ZR; Sanders RC
    Surg Gynecol Obstet; 1990 Jan; 170(1):25-31. PubMed ID: 2104681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
    de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
    J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol in chronic schizophrenia: a controlled study in neuroleptic-treated patients.
    Lindström LH; Persson E
    Br J Psychiatry; 1980 Aug; 137():126-30. PubMed ID: 6107136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.
    Hommer DW; Pickar D; Crawley JN; Weingartner H; Paul SM
    Ann N Y Acad Sci; 1985; 448():542-52. PubMed ID: 3896099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia.
    Adler L; Angrist B; Peselow E; Corwin J; Maslansky R; Rotrosen J
    Br J Psychiatry; 1986 Jul; 149():42-5. PubMed ID: 2877708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. m-Chlorophenylpiperazine effects in neuroleptic-free schizophrenic patients. Evidence implicating serotonergic systems in the positive symptoms of schizophrenia.
    Krystal JH; Seibyl JP; Price LH; Woods SW; Heninger GR; Aghajanian GK; Charney DS
    Arch Gen Psychiatry; 1993 Aug; 50(8):624-35. PubMed ID: 8102048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.
    Josiassen RC; Joseph A; Kohegyi E; Stokes S; Dadvand M; Paing WW; Shaughnessy RA
    Am J Psychiatry; 2005 Jan; 162(1):130-6. PubMed ID: 15625211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quetiapine in schizophrenia: onset of action within the first week of treatment.
    Small JG; Kolar MC; Kellams JJ
    Curr Med Res Opin; 2004 Jul; 20(7):1017-23. PubMed ID: 15265246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results.
    Albus M; von Gellhorn K; Münch U; Naber D; Ackenheil M
    Psychiatry Res; 1986 Sep; 19(1):1-7. PubMed ID: 3538106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Control group bias in randomized atypical antipsychotic medication trials for schizophrenia.
    Woods SW; Gueorguieva RV; Baker CB; Makuch RW
    Arch Gen Psychiatry; 2005 Sep; 62(9):961-70. PubMed ID: 16143728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder.
    Meltzer HY; Arvanitis L; Bauer D; Rein W;
    Am J Psychiatry; 2004 Jun; 161(6):975-84. PubMed ID: 15169685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discontinuation of neuroleptic medication in older, outpatient schizophrenics. A placebo-controlled, double-blind trial.
    Ruskin PE; Nyman G
    J Nerv Ment Dis; 1991 Apr; 179(4):212-4. PubMed ID: 1672547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.